1 / 44

ALLHAT

ALLHAT. Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210. ALLHAT. Introduction and Background.

gaetano-lavery
Download Presentation

ALLHAT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ALLHAT Role of Diureticsin the Prevention of Heart Failure -The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.

  2. ALLHAT Introduction and Background • Heart failure is a major public health problem, especially in persons 65 years of age and older (= number one reason for hospitalizations in this age group). • Age-adjusted incidence per 100,000 person-years during 1990-1999 was 564 for men and 327 for women, age 65-74 years (NEJM, 2002, Framingham) • Five-year age-adjusted survival rate was only 59% among men and 45% for women. • In 91% of HF cases, hypertension is an antecedent (Framingham, JAMA, 1996)

  3. ALLHAT Hypertension Controland Heart Failure • In a meta-analysis of 12 trials of patients with hypertension it was found that, compared to placebo, drug therapy for hypertension prevents over 50% of HF events (Moser, JACC, 1996). • In another meta-analysis, diuretics and beta-blockers (BB) were equally effective in preventing HF events (Psaty, JAMA, 1997).

  4. ALLHAT Hypertension Controland Heart Failure • A meta–analysis of active comparator trials found no significant difference between ACE-inhibitors and diuretics for preventing HF; ACE-inhibitors were more efficacious than CCBs (BPLTT Collaboration, Lancet, 2002). • The INSIGHT trial found that a long-acting nifedipine regimen was associated with a > 2x higher incidence of HF events compared to a diuretic combination (HCTZ/amiolride) (Brown, Lancet, 2000).

  5. ALLHAT Objectives • Characterize HF in ALLHAT by its antecedent risk factors and underlying conditions. • Examine occurrence of HF by treatment group overall, in subgroups, and over time. • Explore relation of initial occurrence of HF to pre-randomization type of BP medication used. • Explore follow-up BP and use of additional drugs as mediating/modifying factors. • Examine post-HF mortality overall and by treatment group.

  6. ALLHAT Randomized Design of ALLHAT Hypertension Trial 42,418 high-risk hypertensive patients 90% previously treated 10% untreated STEP 1 AGENTS Chlorthalidone 12.5-25 mg Lisinopril 10-40 mg Doxazosin 1-8 mg Amlodipine 2.5-10 mg N=9,061 N=9,054 N=9,048 N=15,255 Other AHT Drugs STEP 2 AND 3 AGENTS (5 years) Atenolol 28.0% Clonidine 10.6% Reserpine 4.3% Hydralazine 10.9%

  7. ALLHAT Decision to StopDoxazosin Arm • NHLBI Director accepted recommendation of independent review group to terminate doxazosin arm (early in year 2000), due to: • Futility of finding a significant difference for primary outcome • Statistically significant 25 percent higher rate of major secondary endpoint, combined CVD outcomes, along with twofold higher rate of HF • Detailed HF analyses published (Davis et al. Ann Intern Med 2002).

  8. ALLHAT Heart Failure Data Collection • Hospitalized nonfatal – discharge summary • Hospitalized fatal – death certificate, discharge summary • Nonhospitalized fatal – death certificate • Nonhospitalized nonfatal (treated) – clinician report • 100% review of discharge summaries and death certificates by CTC Medical Reviewers • Queries to clinics if diagnosis questionable

  9. ALLHAT ALLHAT Criteria for HF Evaluation* *ALLHAT Manual of Operations, 5.3.4; adopted from the SHEP trial

  10. ALLHAT Validity of HFOutcome Verified • Traditional risk factors in agreement with previous studies, e.g., Framingham • HF Validation Study confirmed original observed treatment differences • Independent central review using both ALLHAT and Framingham criteria

  11. ALLHAT Heart FailureValidation Study

  12. ALLHAT Inclusion/Exclusion Criteria for Antihypertensive Trial • Men and women > 55 years old • If untreated:  140/90,  180/110 mm Hg (2 visits) • If treated: ≤ 160/100 mm Hg (visit 1), ≤ 180/110 mm Hg (visit 2) • No washout required • At least one additional cardiovascular risk factor • Exclude if symptomatic HF or EF < 35%, creatinine  2 mg/dL, require diuretics, CCB, ACEI, or AB’s for non-BP indication

  13. ALLHAT Step 1Treatment Protocol Step 2/3 drugs –– atenolol, reserpine, clonidine, hydralazine “Non-study” drugs –– all other antihypertensive medications

  14. Baseline Characteristics ALLHAT

  15. ALLHAT Hospitalized/ Fatal Heart Failure by ALLHAT Treatment Group .1 .08 Chlorthalidone Amlodipine Lisinopril .06 Cumulative Event Rate .04 .02 0 0 1 2 3 4 5 6 7 Years

  16. ALLHAT Heart Failure Before and After 1 Year • Observed HF differences were larger earlier in the follow-up. • The lisinopril group had a lower HF rate than the amlodipine group, but event curves did not separate until later. • A test of the proportional hazards assumption for Cox regression revealed that RRs were not constant over time. Therefore, a Cox regression that used a time-dependent indicator variable (<=1 year versus >1 year) was utilized.

  17. ALLHAT Chlorthalidone Amlodipine Lisinopril Hospitalized/ Fatal Heart Failure by ALLHAT Treatment Group Within 1 Year and >1 Year .1 .02 .08 .06 Cumulative Hosp/Fatal HF Rate .01 .04 .02 0 0 0 1 2 3 4 5 6 7 0 .5 1 Years to Hosp/Fatal HF Years to Hosp/Fatal HF

  18. ALLHAT Hospitalized/fatal HF in Subgroups - Amlodipine / Chlorthalidone Relative Risks from Baseline to 1 Year of Follow-up Relative Risk (95% CI) Favors Amlodipine Favors Chlorthalidone Total 2.22 (1.69 - 2.91) Age < 65 2.89 (1.62 - 5.17) Age ≥ 65 2.06 (1.51 - 2.80) Non-Black 2.12 (1.49 - 3.01) Black 2.37 (1.55 - 3.63) Men 2.27 (1.56 - 3.30) Women 2.17 (1.46 - 3.21) Diabetic 2.71 (1.83 - 4.02) Non-Diabetic 1.83 (1.25 - 2.67) 0.50 1 2 3 4 5 6

  19. ALLHAT Hospitalized/fatal HF in Subgroups - Amlodipine / Chlorthalidone Relative Risks After 1 Year of Follow-up Relative Risk (95% CI) Favors Amlodipine Favors Chlorthalidone Total 1.22 (1.08 - 1.38) Age < 65 1.38 (1.10 - 1.73) Age ≥ 65 1.17 (1.02 - 1.35) Non-Black 1.20 (1.04 - 1.39) Black 1.28 (1.03 - 1.58) Men 1.28 (1.09 - 1.50) Women 1.16 (0.97 - 1.39) Diabetic 1.23 (1.04 - 1.46) Non-Diabetic 1.21 (1.02 - 1.43) 0.50 1 2 3 4 5 6

  20. ALLHAT Hospitalized/fatal HF in Subgroups - Lisinopril / Chlorthalidone Relative Risks from Baseline to 1 Year of Follow-up Relative Risk (95% CI) Favors Lisinopril Favors Chlorthalidone Total 2.08 (1.58 - 2.74) Age < 65 2.53 (1.39 - 4.59) Age ≥ 65 1.98 (1.45 - 2.70) Non-Black 2.04 (1.43 - 2.90) Black 2.15 (1.39 - 3.33) Men 1.80 (1.22 - 2.67) Women 2.40 (1.63 - 3.54) Diabetic 1.99 (1.31 - 3.05) Non-Diabetic 2.16 (1.50 - 3.10) 0.50 1 2 3 4 5

  21. ALLHAT 0.96 (0.85 - 1.10) 0.95 (0.74 - 1.23) 0.97 (0.84 - 1.13) 0.90 (0.77 - 1.06) 1.10 (0.88 - 1.37) Total 1.02 (0.86 - 1.21) Age < 65 0.89 (0.73 - 1.09) Age ≥ 65 1.01 (0.84 - 1.22) Non-Black 0.93 (0.77 - 1.12) Black Men Women Diabetic Non-Diabetic Hospitalized/fatal HF in Subgroups - Lisinopril / Chlorthalidone Relative Risks After 1 Year of Follow-up Relative Risk (95% CI) Favors Lisinopril Favors Chlorthalidone 0.50 1 2

  22. ALLHAT HF Development and Relation to Other Outcomes • HF development associated with: • 6.6-fold increase in death rate • 11.7-fold increase in CV death rate • Previous MI → 5.7-fold increased HF risk • Of participants with hospitalized HF: • 72% hospitalized once • 23.3% hospitalized 2-3 times • 4.7% hospitalized 4+ times

  23. ALLHAT Why are hazard ratios not constant throughout? Hypotheses? • Withdrawal from BP meds used prior to enrollment • Time course for effect of first-step (primary) drug • Diuretic – immediate? • ACEI – delayed? • Addition of step-up meds (esp. anti-HF meds) • Differences in BP

  24. ALLHAT Prior Use ofAntihypertensive Agents • Prior medication use associated with  HF risk, especially during first year • RR 1.42 (1.18 – 1.71) • Relative benefits of chlorthalidone consistent with or without prior antihypertensive medication use

  25. ALLHAT Specific PriorAntihypertensive Agents • Data not collected within ALLHAT • Available for 1115 / 1773 HF cases • Case-only analysis • No evidence for any statistically significant interaction between prior drug type (e.g., diuretic) and treatment effect for HF, overall or during the first year

  26. ALLHAT Immediate vsDelayed Effects • Do diuretics have a more immediate effect on HF prevention than ACEI or ARB? • Effect of diuretics begins at trial onset • Several ACEI vs placebo studies suggest that ACEI effect is not immediate • VALUE trial – valsartan vs amlodipine – HF similar in first 2 years, strong trend afterward favoring valsartan

  27. ALLHAT Use of Step-upBP Meds Addition of Step 2 and Step 3 meds could have contributed to lessening or cessation of divergence of HF curves after 1 year.

  28. Open-Label ACEI and Atenolol Use ALLHAT

  29. Open-Label Diuretic and CCB Use ALLHAT

  30. Diuretic, ACEI,or Atenol Use ALLHAT

  31. ALLHAT BP Results by Treatment Group Compared to chlorthalidone: SBP significantly higher in the amlodipine group (~1 mm Hg) and the lisinopril group (~2 mm Hg). Compared to chlorthalidone: DBP significantly lower in the amlodipine group (~1 mm Hg).

  32. ALLHAT BP Differences • Adjustment for follow-up SBP as time-dependent covariates in a Cox regression model only slightly modified the relative risks • Amlodipine/chlorthalidone 2.22  2.16 first year, 1.22  1.18 after 1 year • Lisinopril/chlorthalidone 2.08  2.01 first year, 0.96  0.93 after 1 year

  33. ALLHAT All-Cause Mortality Chlorthalidone Amlodipine Lisinopril .6 .5 .4 Cumulative Event Rate .3 .2 .1 0 0 1 2 3 4 5 6 7 Years from Hospitalized HF to Death

  34. ALLHAT Post-HF Mortality • Mortality rates after hospitalized HF high relative to those seen in ALLHAT overall • 25% vs 5% at 2.5 years, respectively • No significant treatment group differences for post-HF mortality • The reason that the treatment difference for hospitalized HF did not translate into an effect on total mortality is that only 5.6% of all deaths were attributed to HF.

  35. ALLHAT Heart Failureand Total Mortality • Lisinopril-chlorthalidone absolute difference in hospitalized HF over 6 years was 0.4%. • The excess of cases in the lisinopril group = 36 patients. • Case-fatality rate over average follow-up of 2.5 years = 25%. • Thus, 9 excess cases of fatal HF would be expected in the lisinopril group. This is fewer than 1% of all deaths in the lisinopril group (n=1314). • Similar calculations for the amlodipine group: • 154 excess cases of hospitalized HF • Estimated number of fatal HF cases was 39, 3% of the amlodipine deaths (n=1256).

  36. ALLHAT Effect on Total Mortality • HF differences in the trial would not have affected differences in total mortality • Also noted in the BPLTTC analyses • Absolute HF risk low • Increase in RR outweighed by even small reduction in higher absolute risks for stroke and CHD • Differences in # of HF events during trial result in only very small differences in # of deaths • ALLHAT post-trial mortality surveillance to examine this further

  37. ALLHAT Conclusions 1 • Chlorthalidone superior to amlodipine in both time periods • Chlorthalidone superior to lisinopril during the first year • True for subgroups – age, race, sex, diabetes history • Other factors could not individually account for all of the observed treatment differences • Prior antihypertensive meds • Other open-label BP meds • Follow-up BP differences

  38. ALLHAT Conclusions 2 • Developing HF is associated with a high mortality rate (~50% at 5 years) • It may take time for HF differences to translate into detectable mortality differences between treatments • Diuretics are clearly preferred over CCBs overall and over ACE inhibitors, at least in the short term, in preventing HF.

  39. Extra Slides

  40. ALLHAT Placebo-Controlled Trials • Most placebo-controlled trial have used diuretics and/or β-blockers as active regimens • Diuretics & ACEI shown to prevent HF in patients with hypertension • SHEP, HOPE • CCB vs placebo trials less conclusive • Syst-Eur • Meta-analyses – active therapy of hypertension can prevent >40% of HF events • Psaty, Smith, Siscovick, et al.

  41. ALLHAT Active-Controlled Trials • VALUE • STOP Hypertension-2 • ANBP2 • INVEST • CONVINCE – CCB or diuretic/β-blocker • BP reduced similarly, HF 30% more with CCB

  42. ALLHAT BPLTTC Meta-Analyses • CCB-based therapies • NS 20% increase in HF incidence compared with placebo • 33% higher risk of HF compared with diuretic/β-blocker • ACEI-based therapies • 18% fewer HF events than with CCB or placebo • 7% NS higher risk than with diuretic/ β-blocker • CCBs less effective in preventing HF than other regimens • ACEI no more effective in preventing HF than diuretic/ β-blocker

  43. ALLHAT Randomized Designof ALLHAT Amlodipine Chlorthalidone Doxazosin Lisinopril High-risk hypertensive patients ≥ 55 years Consent / Randomize (42,418) Eligible for lipid-lowering Not eligible for lipid-lowering Consent / Randomize (10,355) Pravastatin Usual care Follow for CHD and other outcomes until death or end of study (up to 8 yr).

  44. Event Reduction in SHEP, Syst-Eur, and HOPE SHEP: Systolic Hypertension in the Elderly, n=4,736;chlorthalidone Syst-Eur: Systolic Hypertension in Europe, n=4,695;nitrendipine HOPE: Heart Outcomes Prevention Evaluation Study, n=9,297;ramipril

More Related